Details About Generic Salt ::  Albumin

Main Medicine Class:: Plasma protein fraction   

(al-BYOO-MIN human)

Albuminar-5, Albuminar-25, Albunex, Albutein 5%, Albutein 25%, Buminate 5%, Buminate 25%, Plasbumin-5, Plasbumin-25

Class: Plasma protein fraction

 

Drugs Class ::

 Action Maintains plasma colloid osmotic pressure and serves as carrier of intermediate metabolites in transport and exchange of tissue products.

Indications for Drugs ::

 Indications Symptomatic relief and supportive treatment in management of shock, burns, hypoprothrombinemia, adult respiratory distress syndrome, cardiopulmonary bypass, acute liver failure, acute nephrosis, sequestration of protein-rich fluids, erythrocyte resuspension, hypotension or shock during renal dialysis, hyperbilirubinemia and erythroblastosis fetalis.

Drug Dose ::

 Route/Dosage

Burns

Initial treatment usually consists of large amounts of crystalloid infusions (eg, normal saline, Lactated Ringer’s) with lesser amounts of 5% albumin to maintain adequate plasma volume. After first 24 hr, ratio of albumin and crystalloid should maintain plasma albumin level of » 2.5 g ± 0.5 g/100 ml or total plasma protein level of about 5.2 g/100 ml. This is best achieved with albumin 25% solution.

NORMAL SERUM ALBUMIN, 5%

Shock

Give as rapidly as necessary to improve patient’s condition and restore normal blood volume. ADULTS: Initial dose: IV 500 ml of 5% albumin given as rapidly as tolerated. If response in 30 min is inadequate, give additional 500 ml. In patients with slightly low or normal blood volume, rate is 2 to 4 ml/min. CHILDREN: IV Rate of administration is ¼ to ½ adult rate. NEONATES & INFANTS: IV 10 to 20 ml/kg 5% albumin based on clinical response, BP and assessment of anemia.

Hypoproteinemia

To replace protein loss, 5% albumin may be given.

ALBUMIN HUMAN, 25%

Shock

ADULTS & CHILDREN: Initial dose: IV Determined by patient’s condition and response to treatment. Therapy is guided by degree of venous or pulmonary congestion or Hct measurements.

Hypoproteinemia

ADULTS: IV 50 to 75 g/day at rate not exceeding 2 ml/min. CHILDREN: IV 25 g/day at rate not exceeding 2 ml/min.

Acute Nephrosis

ADULTS: IV 100 ml 25% albumin in combination with loop diuretic repeated daily for 7 to 10 days.

Renal Dialysis

ADULTS: IV Approximately 100 ml 25% albumin.

Hyperbilirubinemia and Erythroblastosis Fetalis

NEONATES & INFANTS: IV 1 g/kg 1 to 2 hr before transfusion.

Contraindication ::

 Contraindications Severe anemia; cardiac failure; renal insufficiency; presence of normal or increased intravascular volume; chronic nephrosis; hypoprothrombinemic states associated with chronic cirrhosis; malabsorption; protein-losing enteropathies, pancreatic insufficiency; undernutrition.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Special risk patients: Circulatory overload may develop in patients with CHF, renal insufficiency or stabilized chronic anemia. Concomitant blood administration: Relative anemia can be avoided by supplementing or replacing large quantities of albumin with whole blood. Hepatic or renal impairment: Caution is needed because of added protein load.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CV: Hypotension after rapid infusion (> 10 ml/min) or intra-arterial administration to patients undergoing cardiopulmonary bypass; rapid administration may cause vascular overload, dyspnea or pulmonary edema. OTHER: Allergic or pyogenic reactions (characterized by fever and chills).

Drug Mode of Action ::  

 Action Maintains plasma colloid osmotic pressure and serves as carrier of intermediate metabolites in transport and exchange of tissue products.

Drug Interactions ::

 Interactions None well documented.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note severe anemia, hepatic, or renal impairment.
• Assess baseline Hct before infusion.
• Take pulse and BP before and during infusion.
• Monitor liver and kidney function, Hct, electrolytes, plasma albumin, and total serum protein before and during therapy.
• Assess for signs of fluid overload before and during infusion.
• If venous or pulmonary congestion worsens or if hypotension occurs, slow or discontinue infusion and notify physician.
• Monitor I&O.
• Monitor for dehydration. Patient may require additional fluids.
• If patient has sustained injury or has had surgery, observe for new bleeding points as BP increases.
• Monitor for allergic or pyogenic reactions characterized by fever and chills. If these symptoms occur, discontinue treatment and notify physician.
• Do not infuse if intravascular volume is normal or increased or if patient has potential for fluid volume overload.

Drug Storage/Management ::

 Administration/Storage

• Administer by IV infusion only, using accompanying administration set and large-gauge needle or catheter.
• Give medication as supplied; do not dilute.
• Administer slowly to prevent too-rapid expansion of blood volume. Exception: May be administered rapidly if there is severe loss of plasma volume.
• Do not administer if solution is cloudy or sediment is present.
• Store at room temperature. Do not freeze.

Drug Notes ::

 Patient/Family Education

• Explain rationale for infusion of drug and need for frequent monitoring.
• Instruct patient to report the following symptoms to physician: Fever, chills, headache, back pain.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.